Navigation Links
Chaffin Luhana Alerts Actos Patients to Updated MDL Trial Dates
Date:4/9/2013

New York, NY (PRWEB) April 09, 2013

Chaffin Luhana LLP, a national plaintiffs-only law firm, today reminded plaintiffs and patients who have taken Actos that the first bellwether trials in the Actos MDL have been moved up. Judge Rebecca F. Doherty promised last year that she would move the litigation along as quickly as possible, and on February 19, 2013, she ordered that the first trial to begin on January 27, 2014, with the second scheduled for April 14, 2014 (Case 6:13-cv-00345-RFD-PJH, U.S. District Court, Western District of Louisiana, Scheduling Order: Pilot Bellwether Program (First Trial)).

“This reflects a new accelerated schedule for federal Actos cases, and should help plaintiffs to see their lawsuits resolved in a more timely manner,” said Eric Chaffin, co-founder of the firm. “Many of the plaintiffs involved in these lawsuits are elderly, and can’t afford to wait around for years to discover the outcome of their claims.”

Back in June 2012, Judge Doherty had scheduled the first bellwether trials to begin in November 2014, but in the recent court order she changed those dates. The updated program establishes a “streamlined trial preparation schedule for a minimum of two Pilot Bellwether trials,” and is imposed “so as to serve the very important goal of moving these proceedings toward completion of this court’s responsibilities in a reasonable time.”

The first Actos lawsuit has already gone to trial in Los Angeles, California, with plaintiff Jack Cooper alleging that manufacturer Takeda failed to warn about the serious risk of bladder cancer associated with long-term Actos use (Feeley & Cronin, “Takeda Faces First Trial Over Actos Diabetes Drug in L.A.,” Bloomberg, 2/18/2013). Over 3,000 other plaintiffs have made similar claims against the company, with all federal cases consolidated into the Western District of Louisiana on December 29, 2011 (MDL No. 2299).

Litigation against Takeda expanded after the June 2011 FDA warning concerning the link between Actos and bladder cancer (FDA Drug Safety Communication, 6/15/2011). The agency reviewed the five-year results of a 10-year ongoing epidemiological study, and reported that patients taking the type 2 diabetes drug for more than 12 months may be at a 40 percent increased risk of bladder cancer. In August 2011, the FDA approved updated drug labels that contained the new information (FDA Drug Safety Communication, 8/4/2011).

Judge Doherty noted in her order that the deadlines for the bellwether trials “should be considered hard and fast,” and will not be “extended, continued, or delayed” unless extraordinarily good cause is shown. She acknowledged that the schedule will place “extraordinary burdens” on the court, counsel and parties, but encouraged all to do what is necessary to prepare these trials to begin on time.

Chaffin Luhana LLP has a successful history of protecting the rights of those affected by the serious side effects of medications like Actos. Partners Eric Chaffin and Roopal Luhana represent high-profile cases in federal and state courts across the country, and provide new online resource centers for clients and the public. To date, Mr. Chaffin and Ms. Luhana along with co-counsel have been involved in recovering over $900 million for injured consumers. Both have been named to the prestigious New York Metro Super Lawyers list, and though unable to guarantee results, the firm has a distinguished track record of success and is highly committed to each case.

If you or a loved one has suffered an injury after taking Actos, contact Chaffin Luhana LLP for a free and confidential case review at 1-888-480-1123, or visit the firm website at http://www.chaffinluhana.com.

CONTACT
Eric T. Chaffin, Esq.
CHAFFIN LUHANA LLP
600 Third Ave., 12th Floor
New York, New York 10016                                                                                                                                                            
Toll Free Telephone: (888) 480-1123
Toll Free Fax: (888) 499-1123

Attorney Advertising. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Read the full story at http://www.prweb.com/releases/2013/4/prweb10605248.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. TxtWatcher Alerts Parents About Kids Texting While Driving
2. Internet searches can identify drug safety issues well ahead of public alerts
3. NOAA adds red tide alerts to Beach Hazards Statements
4. DrugRisks Update: Doctor Testifies Actos Main Cause of Bladder Cancer in Trial
5. 2013 Actos Bladder Cancer Claims Now Being Investigated by Resource4thePeople Attorneys
6. DrugRisk Center Adds Latest on First of 3,000 Actos Bladder Cancer Trials
7. DrugRisks Adds Update from First Actos Trial of Patient Alleging Bladder Cancer
8. Drug Safety Center Update: Employee Alleges Actos Maker Valued Sales Over Safety
9. DrugRisk Update: Evidence Submitted in Actos Lawsuit Suggests Drug Maker Knew of Cancer Risks
10. Actos Lawsuit News: Bernstein Liebhard LLP Notes Latest Scheduling Order in Actos Bladder Cancer Litigation
11. US Drug Watchdog Now Urges All Diabetics Nationwide Who Used the Diabetes Drug Actos and now have Bladder Cancer to Call The Johnson Law Group For A Legal Evaluation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... 08, 2016 , ... The Florida Hospital Tampa Wound Healing ... Society (UHMS), the leading authority in hyperbaric medicine. This accreditation identifies the Institute ... and facilities have earned this distinction. This is the second time the Florida ...
(Date:12/8/2016)... JENNERSVILLE, Pa. (PRWEB) , ... December 08, 2016 ... ... Penn Medicine Southern Chester County, a Property owned by an affiliate of Seavest, ... 72,000 square foot Penn Medicine Southern Chester County ambulatory care center (ACC) was ...
(Date:12/8/2016)... ... December 08, 2016 , ... David J. Dykeman ... law firm Greenberg Traurig, LLP, will speak at DeviceTalks West, Dec. 12, 2016, at ... DeviceTalks series, and attorneys from the firm’s global Life Sciences & Medical Technology Group ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... development solutions for drugs, biologics and consumer health products, today announced that it ... up in 2006 as a non-profit organization to unite pharmaceutical and healthcare companies ...
(Date:12/8/2016)... City, Ga (PRWEB) , ... December 08, 2016 ... ... moving as soon after surgery as possible. With this in mind, SIGVARIS has ... thrombosis (DVT or blood clot) during bed rest and provide the benefits of ...
Breaking Medicine News(10 mins):
(Date:12/9/2016)... aTyr Pharma, Inc. (Nasdaq: LIFE ), a biotherapeutics company ... severe, rare diseases, today announced that senior management will participate in ... Conference at the InterContinental Barclay Hotel in New York ... ET. About aTyr Pharma ... aTyr Pharma is engaged in the ...
(Date:12/9/2016)... , Dec. 9, 2016  Forge Therapeutics, Inc. ... (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) to ... for the treatment of bacterial infections including those ... recognized as an attractive antibacterial target for more ... of suitable chemical starting points has hampered its ...
(Date:12/8/2016)... -- The global biosurgery market is expected to grow at ... 2016 to 2021. The market is poised to reach ... in 2016. The market is primarily driven by rising ... and spinal problems, increasing clearance of biosurgery products by ... management. In this report, the biosurgery market ...
Breaking Medicine Technology: